Trial Profile
A multi-center, double-blind, placebo-controlled therapeutic trial to determine whether natural huperzine A improves cognitive function.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 May 2011
Price :
$35
*
At a glance
- Drugs Huperzine A (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- 19 Apr 2011 Primary endpoint 'Alzheimer's Disease Assessment Scale-cognitive subscale' has not been met, as published in Neurology.
- 19 Apr 2011 Results published in Neurology.
- 02 Feb 2008 Top-line results from the double-blind part of the study reported in a Neuro-Hitech media release.